Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial

Ann Oncol. 2014 Apr;25(4):910-911. doi: 10.1093/annonc/mdu034.

Authors

C Criscitiello¹, H A Azim², E de Azambuja², I T Rubio³

Affiliations

¹ Department of Medical Oncology, Istituto Europeo di Oncologia, Milan, Italy. Electronic address: [email protected].
² BrEAST Data Centre and Department of Medicine, Clinical Oncology, Brussels, Belgium.
³ Breast Surgical Onclogy Unit, Universitario Vall D'Hebron, Barcelona, Spain.

PMID: 24667722
DOI: 10.1093/annonc/mdu034

No abstract available

Publication types

Letter
Comment

MeSH terms

Breast Neoplasms / drug therapy*
Breast Neoplasms / surgery*
Female
Humans
Mastectomy, Segmental*
Neoadjuvant Therapy*
Receptor, ErbB-2 / metabolism*

Substances

Receptor, ErbB-2